Halt Medical Inc. - Acessa Procedure
Halt Medical Inc. - Acessa Procedure is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Halt Medical Inc. - Acessa Procedure.
Halt Medical Inc. - Acessa Procedure is a company.
Key people at Halt Medical Inc. - Acessa Procedure.
Halt Medical, Inc. develops the Acessa System, a minimally invasive medical device for treating symptomatic uterine fibroids through laparoscopic radiofrequency ablation.[1][2] The Acessa Procedure targets fibroids with heat to shrink and soften them, offering a non-hormonal, uterine-sparing alternative to hysterectomy or myomectomy, primarily serving women experiencing heavy bleeding, pain, or pressure from fibroids.[1][2][3] It solves the problem of fibroid symptoms affecting up to 77% of women by enabling outpatient treatment with quick recovery—patients often return to work in 4-5 days—while preserving fertility and avoiding major surgery.[2]
The company, based in Brentwood, California, has raised $66.8 million in total funding across three rounds, with the most recent at $63.3 million, indicating strong investor interest in its growth potential despite limited recent public news.[1]
Halt Medical, Inc. emerged in the medical device space focused on women's health, with early milestones including the first commercial use of the Acessa Procedure in 2012, performed by Dr. Berman at Berry Surgery Center in Farmington Hills, Michigan, for uterine fibroid treatment.[4] The idea stemmed from addressing gaps in fibroid care, developing a laparoscopic technology that uses ultrasound-guided radiofrequency energy to ablate fibroids precisely.[1][2][3]
Founders and exact founding year details are not specified in available sources, but the company's evolution centered on clinical validation and commercialization of the Acessa System, culminating in an acquisition agreement announced via PR Newswire, where Halt Medical agreed to be acquired, likely to scale its uterine-sparing innovation.[5]
Halt Medical rides the trend of minimally invasive gynecology, amid rising demand for uterine-sparing fibroid treatments as awareness grows—77% lifetime prevalence drives market expansion.[2] Timing aligns with advances in radiofrequency ablation and laparoscopy, reducing surgical risks in women's health, where fibroids impact quality of life for millions.[1][2]
Market forces like aging populations, fertility preservation priorities, and shifts from invasive surgeries favor Acessa, influencing the ecosystem by setting a new standard for outpatient fibroid care and inspiring similar device innovations.[1][3]
Post-acquisition by Acessa Health Inc., Halt Medical's Acessa System is poised for wider adoption through expanded distribution and clinical integration.[3] Trends like personalized women's health tech and value-based care will shape its path, potentially boosting procedure volumes as data on long-term outcomes accumulates. Its influence may evolve by normalizing ablation as first-line therapy, reducing hysterectomy rates and enhancing patient-centered gynecology—building on its funding-fueled foundation to redefine fibroid management.[1][2][5]
Key people at Halt Medical Inc. - Acessa Procedure.
